Tarsus Pharmaceuticals Files 8-K: Material Definitive Agreement

TL;DR

Tarsus Pharma inked a big deal on Feb 29th. 8-K filed.

AI Summary

On February 29, 2024, Tarsus Pharmaceuticals, Inc. entered into a Material Definitive Agreement. The company, incorporated in Delaware with its principal executive offices in Irvine, CA, filed this 8-K report with the SEC.

Why It Matters

This filing indicates a significant contractual development for Tarsus Pharmaceuticals, which could impact its business operations and future strategies.

Risk Assessment

Risk Level: medium — Material Definitive Agreements can introduce new risks or opportunities that are not yet fully understood by the market.

Key Numbers

• 001-39614 — SEC File Number (Identifies the company's filing history with the SEC.)
• 81-4717861 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Tarsus Pharmaceuticals, Inc. (company) — Registrant
• February 29, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• Irvine, CA (location) — Principal executive offices
• 001-39614 (identifier) — Commission File Number
• 81-4717861 (identifier) — I.R.S. Employer Identification No.

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share TARS The Nasdaq
• $32.00 — price to the public in the Offering is $32.00 per share and $31.9999 per pre-funded w
• $31.9999 — in the Offering is $32.00 per share and $31.9999 per pre-funded warrant, which is the pr
• $30.08 — he Underwriting Agreement at a price of $30.08 per share and a price of $30.0799 per p
• $30.0799 — rice of $30.08 per share and a price of $30.0799 per pre-funded warrant, respectively. U
• $93.7 m — fering are expected to be approximately $93.7 million, after deducting underwriting dis
• $100.0 million — ease to announce a proposed offering of $100.0 million of shares and pre-funded warrants pursu
• $100.0 Million — 2024, titled "Tarsus Announces Proposed $100.0 Million Public Offering". 99.2 Press releas

Filing Documents

• d759306d8k.htm (8-K) — 34KB
• d759306dex11.htm (EX-1.1) — 301KB
• d759306dex41.htm (EX-4.1) — 67KB
• d759306dex51.htm (EX-5.1) — 13KB
• d759306dex991.htm (EX-99.1) — 9KB
• d759306dex992.htm (EX-99.2) — 10KB
• g759306g0301143011164.jpg (GRAPHIC) — 4KB
• g759306g0301143025981.jpg (GRAPHIC) — 4KB
• g759306g0301145037410.jpg (GRAPHIC) — 6KB
• g759306g11y65.jpg (GRAPHIC) — 5KB
• g759306g36u78.jpg (GRAPHIC) — 4KB
• 0001193125-24-056209.txt ( ) — 703KB
• tars-20240229.xsd (EX-101.SCH) — 3KB
• tars-20240229_lab.xml (EX-101.LAB) — 18KB
• tars-20240229_pre.xml (EX-101.PRE) — 11KB
• d759306d8k_htm.xml (XML) — 4KB

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1.1 Underwriting Agreement, dated February 29, 2024, by and among the Company, Goldman Sachs & Co. LLC, BofA Securities, Inc. and Guggenheim Securities, LLC. 4.1 Form of Pre-Funded Warrant 5.1 Opinion and Consent of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian LLP. 23.1 Consent of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian LLP (included in Exhibit 5.1). 99.1 Press release issued by the Company, dated February 29, 2024, titled "Tarsus Announces Proposed $100.0 Million Public Offering". 99.2 Press release issued by the Company, dated February 29, 2024, titled "Tarsus Announces Pricing of $100.0 Million Public Offering". 104 Cover Page Interactive Data File (embedded within XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 1, 2024 Tarsus Pharmaceuticals, Inc. By: /s/ Jeffrey S. Farrow Jeffrey S. Farrow Chief Financial Officer and Chief Strategy Officer (Principal Financial Officer and Principal Accounting Officer)

View Full Filing

View this 8-K filing on SEC EDGAR